BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31260128)

  • 1. Volumetric changes in pharyngeal structures following head and neck cancer chemoradiation therapy.
    Hinther A; Samson N; Lau H; Quon H; Banerjee R; Lysack JT; Grendarova P; Matthews TW; Randall DR
    Laryngoscope; 2020 Mar; 130(3):597-602. PubMed ID: 31260128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
    Petkar I; Rooney K; Roe JW; Patterson JM; Bernstein D; Tyler JM; Emson MA; Morden JP; Mertens K; Miles E; Beasley M; Roques T; Bhide SA; Newbold KL; Harrington KJ; Hall E; Nutting CM
    BMC Cancer; 2016 Oct; 16(1):770. PubMed ID: 27716125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma.
    Saksø M; Andersen E; Bentzen J; Andersen M; Johansen J; Primdahl H; Overgaard J; Eriksen JG
    Acta Oncol; 2019 Oct; 58(10):1495-1501. PubMed ID: 31519130
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
    Maring S; Elsayad K; Stenner M; Rudack C; Haverkamp U; Rehkämper J; Wardelmann E; Eich HT
    Oncol Res Treat; 2018; 41(12):736-743. PubMed ID: 30419553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
    Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
    Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma.
    Hosni A; Dixon PR; Rishi A; Au M; Xu W; Song Y; Chepeha DB; Goldstein DP; Huang SH; Kim J; O'Sullivan B; Waldron J; Bratman SV; de Almeida JR
    JAMA Otolaryngol Head Neck Surg; 2016 Dec; 142(12):1208-1215. PubMed ID: 27812692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A swallow preservation protocol improves function for veterans receiving chemoradiation for head and neck cancer.
    Peng KA; Kuan EC; Unger L; Lorentz WC; Wang MB; Long JL
    Otolaryngol Head Neck Surg; 2015 May; 152(5):863-7. PubMed ID: 25829388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation dose to the tongue and velopharynx predicts acoustic-articulatory changes after chemo-IMRT treatment for advanced head and neck cancer.
    Jacobi I; Navran A; van der Molen L; Heemsbergen WD; Hilgers FJ; van den Brekel MW
    Eur Arch Otorhinolaryngol; 2016 Feb; 273(2):487-94. PubMed ID: 25638526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation-Associated Chronic Dysphagia Assessment by Flexible Endoscopic Evaluation of Swallowing (FEES) in Head and Neck Cancer Patients: Swallowing-Related Structures and Radiation Dose-Volume Effect.
    Ozkaya Akagunduz O; Eyigor S; Kirakli E; Tavlayan E; Erdogan Cetin Z; Kara G; Esassolak M
    Ann Otol Rhinol Laryngol; 2019 Feb; 128(2):73-84. PubMed ID: 30343589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical and Radiobiological Evaluation of Accelerated Intensity Modulated Radiotherapy for Locally Advanced Head and Neck Cancer and Comparison with Short-Term Clinical Outcomes.
    Buchapudi RR; Manickam R; M R AK; C R TP; Chandraraj V; Pyakuryal A; Narayanasamy G
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2463-2470. PubMed ID: 31450921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Adjuvant Therapy With Chemoradiation vs Radiation Alone for Patients With HPV-Negative N2a Head and Neck Cancer.
    Yan F; Li H; Kaczmar JM; Sharma AK; Day TA; Neskey DM; Pipkorn P; Zenga J; Graboyes EM
    JAMA Otolaryngol Head Neck Surg; 2020 Dec; 146(12):1109-1119. PubMed ID: 32790830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck.
    Caudell JJ; Schaner PE; Desmond RA; Meredith RF; Spencer SA; Bonner JA
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):403-9. PubMed ID: 19467801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Maguire PD; Neal CR; Hardy SM; Schreiber AM
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life assessment of Volumetric Modulated Arc Therapy (VMAT) toxicity in Head and Neck Squamous Cell Carcinoma (HNSCC) treatment.
    Moncharmont C; Vallard A; Mengue Ndong S; Guy JB; Saget C; Méry B; Langrand-Escure J; de Laroche G; Goyet D; Prades JM; Fournel P; Magné N
    Acta Otolaryngol; 2016; 136(2):181-8. PubMed ID: 26503806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy.
    Mollnar S; Pondorfer P; Kasparek AK; Reinisch S; Moik F; Stotz M; Halm M; Szkandera J; Terbuch A; Eisner F; Gerger A; Kapp KS; Partl R; Vasicek S; Weiland T; Pichler M; Stöger H; Thurnher D; Posch F
    Clin Transl Oncol; 2021 Mar; 23(3):543-553. PubMed ID: 32671728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy.
    Hansen CR; Friborg J; Jensen K; Samsøe E; Johnsen L; Zukauskaite R; Grau C; Maare C; Johansen J; Primdahl H; Bratland Å; Kristensen CA; Andersen M; Eriksen JG; Overgaard J
    Acta Oncol; 2019 Oct; 58(10):1410-1415. PubMed ID: 31432744
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
    Mavroidis P; Price A; Fried D; Kostich M; Amdur R; Mendenhall W; Liu C; Das S; Marks LB; Chera B
    Radiother Oncol; 2017 Aug; 124(2):240-247. PubMed ID: 28712533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Fried D; Price A; Amdur RJ; Mendenhall W; Lu C; Das S; Sheets N; Marks L; Mavroidis P
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1022-1027. PubMed ID: 28721884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age most significant predictor of requiring enteral feeding in head-and-neck cancer patients.
    Sachdev S; Refaat T; Bacchus ID; Sathiaseelan V; Mittal BB
    Radiat Oncol; 2015 Apr; 10():93. PubMed ID: 25896830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Skeletal Muscle Mass Is a Risk Factor for Aspiration Pneumonia During Chemoradiotherapy.
    Endo K; Ueno T; Hirai N; Komori T; Nakanishi Y; Kondo S; Wakisaka N; Yoshizaki T
    Laryngoscope; 2021 May; 131(5):E1524-E1529. PubMed ID: 33030229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.